Page 11 - hypertension_newsletter
P. 11

REFLECTIONS
                                                                                                                   Hypertension
     Hypertension Global Newsletter #10 2026


     Additionally, the study found a strong correlation with baseline BP: for every 10 mmHg lower a patient’s starting BP is, the efficacy
     of monotherapies drops by an average of 1.3 mmHg. These findings reinforce that combination therapy is more effective than   Hypertension
     increasing the dose of a single antihypertensive agent.


                         Predicted reductions in SBP for different combinations of five antihypertensives
                         at different doses as single, dual, or triple therapy for a baseline SBP of 154 mmHg



























     Mean (95% prediction intervals) SBP reduction was estimated by adding the expected BP reduction from derived meta-regression equations for the respective
     monotherapy components, accounting for a lower baseline BP for the second or third components. Different colours indicate efficacy intensity: low (red), moderate
     (yellow), and high (green) correspond to SBP reductions of <10 mmHg, 10–19.9 mmHg, and ≥20 mmHg, respectively, from a baseline of 154 mmHg, with darker shades
     corresponding to greater reductions. Mean reductions are larger for higher baseline BPs and smaller for lower baseline BPs.


     The authors noted a few limitations to the study. The study design
     restricted the researchers’ ability to identify individual effect   CLINICAL PEARLS FROM THE FACULTY
     modifiers. Furthermore, active drug comparisons and tolerability
     were not evaluated, meaning the resulting efficacy calculator may
     contain inaccuracies. Because of this, the authors caution that
     prescribers should not rely entirely on expected changes in BP
     based on this predictive model; nonetheless, these trial-derived
     estimates provide a foundation for evidence-informed prescribing.
     By moving away from trial-and-error dosing and utilizing the newly
     developed efficacy classifications (low, moderate, high intensity),
     clinicians can pre-emptively select the precise combination
     therapies needed to rapidly and effectively close the global gap in
     hypertension control.
                                                                          WATCH
                                                                          VIEW COMMENTARY FROM DR.
               CLICK HERE                                                 FIKRLE DISCUSSING THE CLINICAL
               FOR THE LINK TO FULL ARTICLE                               RELEVANCE OF THE ARTICLE.















          TABLE OF CONTENTS
   6   7   8   9   10   11   12   13   14   15   16